MARKET WIRE NEWS

What to Know About This Fund's $50 Million Exit From Ascendis Pharma

Source: Motley Fool

2026-05-14 15:05:52 ET

On May 14, 2026, Siren disclosed in an SEC filing that it sold its entire holding of Ascendis Pharma A/S (NASDAQ:ASND) , liquidating 235,862 shares in an estimated $52.87 million transaction based on quarterly average pricing.

According to a SEC filing dated May 14, 2026, Siren sold its entire holding of 235,862 Ascendis Pharma A/S shares. The estimated transaction value is $52.87 million, calculated using the average share price during the first quarter of 2026. The fund’s quarter-end position in Ascendis Pharma A/S fell by $50.30 million, a figure that includes both the sale and price effects.

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark, focused on innovative therapies for rare endocrine and pediatric diseases. The company leverages its TransCon technology platform to develop long-acting prodrugs that address significant unmet medical needs.

Continue reading

Ascendis Pharma A/S

NASDAQ: ASND

ASND Trading

-3.48% G/L:

$252.895 Last:

394,444 Volume:

$262.15 Open:

mwn-press-release-boost Ad 900
?>

ASND Latest News

$13,394,473,228
60,082,592
N/A
105
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hellerup

Check Your Online Brokerage For ASND

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App